Management of hypertension in patients with left ventricular hypertrophy

Cesare Cuspidi, Carla Sala, Alberto Zanchetti

Research output: Contribution to journalArticlepeer-review


Left ventricular hypertrophy (LVH) is a cardinal manifestation of organ damage in patients with arterial hypertension. Identifying LVH is a fundamental step in evaluating hypertensive patients, because clinical and epidemiologic studies have shown this condition has a strong independent adverse prognostic significance. LVH is an integrated marker of cardiovascular risk, reflecting hypertension's hemodynamic and nonhemodynamic effects on the heart. Reversing LVH is an intermediate goal of antihypertensive therapy. Pharmacologic strategies to reverse LVH should be based on combining two or more drugs: a renin-angiotensin system blocker (ie, angiotensin-converting enzyme inhibitor or angiotensin receptor antagonist), and a calcium antagonist or low-dose diuretic. Successful therapeutic plans should also include nonpharmacologic interventions to promote LVH regression.

Original languageEnglish
Pages (from-to)498-505
Number of pages8
JournalCurrent Hypertension Reports
Issue number6
Publication statusPublished - Dec 2007

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Management of hypertension in patients with left ventricular hypertrophy'. Together they form a unique fingerprint.

Cite this